IBDEI1DY ; ; 01-FEB-2022
;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
Q:'DIFQR(358.3) F I=1:2 S X=$T(Q+I) Q:X="" S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E S @X=Y
Q Q
;;^UTILITY(U,$J,358.3,22412,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,22412,1,3,0)
;;=3^Rising PSA After Tx for Prostate CA
;;^UTILITY(U,$J,358.3,22412,1,4,0)
;;=4^R97.21
;;^UTILITY(U,$J,358.3,22412,2)
;;=^5139228
;;^UTILITY(U,$J,358.3,22413,0)
;;=R82.81^^73^961^85
;;^UTILITY(U,$J,358.3,22413,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,22413,1,3,0)
;;=3^Pyuria
;;^UTILITY(U,$J,358.3,22413,1,4,0)
;;=4^R82.81
;;^UTILITY(U,$J,358.3,22413,2)
;;=^101879
;;^UTILITY(U,$J,358.3,22414,0)
;;=I25.118^^73^961^8
;;^UTILITY(U,$J,358.3,22414,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,22414,1,3,0)
;;=3^Athscl Hrt Dis of Native Cor Art w/ Oth Angina
;;^UTILITY(U,$J,358.3,22414,1,4,0)
;;=4^I25.118
;;^UTILITY(U,$J,358.3,22414,2)
;;=^5007110
;;^UTILITY(U,$J,358.3,22415,0)
;;=J44.0^^73^961^17
;;^UTILITY(U,$J,358.3,22415,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,22415,1,3,0)
;;=3^COPD w/ Lower Respiratory Infection
;;^UTILITY(U,$J,358.3,22415,1,4,0)
;;=4^J44.0
;;^UTILITY(U,$J,358.3,22415,2)
;;=^5008239
;;^UTILITY(U,$J,358.3,22416,0)
;;=J44.1^^73^961^16
;;^UTILITY(U,$J,358.3,22416,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,22416,1,3,0)
;;=3^COPD w/ Acute Exacerbation
;;^UTILITY(U,$J,358.3,22416,1,4,0)
;;=4^J44.1
;;^UTILITY(U,$J,358.3,22416,2)
;;=^5008240
;;^UTILITY(U,$J,358.3,22417,0)
;;=I50.22^^73^961^15
;;^UTILITY(U,$J,358.3,22417,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,22417,1,3,0)
;;=3^CHF-Systolic (HFrEF),Chronic
;;^UTILITY(U,$J,358.3,22417,1,4,0)
;;=4^I50.22
;;^UTILITY(U,$J,358.3,22417,2)
;;=^5007241
;;^UTILITY(U,$J,358.3,22418,0)
;;=I50.32^^73^961^13
;;^UTILITY(U,$J,358.3,22418,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,22418,1,3,0)
;;=3^CHF-Diastolic (HFpEF),Chronic
;;^UTILITY(U,$J,358.3,22418,1,4,0)
;;=4^I50.32
;;^UTILITY(U,$J,358.3,22418,2)
;;=^5007245
;;^UTILITY(U,$J,358.3,22419,0)
;;=I50.42^^73^961^12
;;^UTILITY(U,$J,358.3,22419,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,22419,1,3,0)
;;=3^CHF-Combined Systolic & Diastolic,Chronic
;;^UTILITY(U,$J,358.3,22419,1,4,0)
;;=4^I50.42
;;^UTILITY(U,$J,358.3,22419,2)
;;=^5007249
;;^UTILITY(U,$J,358.3,22420,0)
;;=I50.84^^73^961^14
;;^UTILITY(U,$J,358.3,22420,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,22420,1,3,0)
;;=3^CHF-End Stage
;;^UTILITY(U,$J,358.3,22420,1,4,0)
;;=4^I50.84
;;^UTILITY(U,$J,358.3,22420,2)
;;=^5151391
;;^UTILITY(U,$J,358.3,22421,0)
;;=E11.22^^73^961^27
;;^UTILITY(U,$J,358.3,22421,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,22421,1,3,0)
;;=3^DM Type 2 w/ Chronic Kidney Disease
;;^UTILITY(U,$J,358.3,22421,1,4,0)
;;=4^E11.22
;;^UTILITY(U,$J,358.3,22421,2)
;;=^5002630
;;^UTILITY(U,$J,358.3,22422,0)
;;=E11.21^^73^961^28
;;^UTILITY(U,$J,358.3,22422,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,22422,1,3,0)
;;=3^DM Type 2 w/ Nephropathy,Unspec
;;^UTILITY(U,$J,358.3,22422,1,4,0)
;;=4^E11.21
;;^UTILITY(U,$J,358.3,22422,2)
;;=^5002629
;;^UTILITY(U,$J,358.3,22423,0)
;;=E11.42^^73^961^32
;;^UTILITY(U,$J,358.3,22423,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,22423,1,3,0)
;;=3^DM Type 2 w/ Peripheral Neuropathy
;;^UTILITY(U,$J,358.3,22423,1,4,0)
;;=4^E11.42
;;^UTILITY(U,$J,358.3,22423,2)
;;=^5002646
;;^UTILITY(U,$J,358.3,22424,0)
;;=E11.43^^73^961^26
;;^UTILITY(U,$J,358.3,22424,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,22424,1,3,0)
;;=3^DM Type 2 w/ Autonomic Neuropathy
--- Routine Detail --- with STRUCTURED ROUTINE LISTING ---[H[J[2J[HIBDEI1DY 3779 printed Nov 22, 2024@17:17:02 Page 2
IBDEI1DY ; ; 01-FEB-2022
+1 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
+2 if 'DIFQR(358.3)
QUIT
FOR I=1:2
SET X=$TEXT(Q+I)
if X=""
QUIT
SET Y=$EXTRACT($TEXT(Q+I+1),4,999)
SET X=$EXTRACT(X,4,999)
if $ASCII(Y)=126
SET I=I+1
SET Y=$EXTRACT(Y,2,999)_$EXTRACT($TEXT(Q+I+1),5,999)
if $ASCII(Y)=61
SET Y=$EXTRACT(Y,2,999)
XECUTE NO
IF '$TEST
SET @X=Y
Q QUIT
+1 ;;^UTILITY(U,$J,358.3,22412,1,0)
+2 ;;=^358.31IA^4^2
+3 ;;^UTILITY(U,$J,358.3,22412,1,3,0)
+4 ;;=3^Rising PSA After Tx for Prostate CA
+5 ;;^UTILITY(U,$J,358.3,22412,1,4,0)
+6 ;;=4^R97.21
+7 ;;^UTILITY(U,$J,358.3,22412,2)
+8 ;;=^5139228
+9 ;;^UTILITY(U,$J,358.3,22413,0)
+10 ;;=R82.81^^73^961^85
+11 ;;^UTILITY(U,$J,358.3,22413,1,0)
+12 ;;=^358.31IA^4^2
+13 ;;^UTILITY(U,$J,358.3,22413,1,3,0)
+14 ;;=3^Pyuria
+15 ;;^UTILITY(U,$J,358.3,22413,1,4,0)
+16 ;;=4^R82.81
+17 ;;^UTILITY(U,$J,358.3,22413,2)
+18 ;;=^101879
+19 ;;^UTILITY(U,$J,358.3,22414,0)
+20 ;;=I25.118^^73^961^8
+21 ;;^UTILITY(U,$J,358.3,22414,1,0)
+22 ;;=^358.31IA^4^2
+23 ;;^UTILITY(U,$J,358.3,22414,1,3,0)
+24 ;;=3^Athscl Hrt Dis of Native Cor Art w/ Oth Angina
+25 ;;^UTILITY(U,$J,358.3,22414,1,4,0)
+26 ;;=4^I25.118
+27 ;;^UTILITY(U,$J,358.3,22414,2)
+28 ;;=^5007110
+29 ;;^UTILITY(U,$J,358.3,22415,0)
+30 ;;=J44.0^^73^961^17
+31 ;;^UTILITY(U,$J,358.3,22415,1,0)
+32 ;;=^358.31IA^4^2
+33 ;;^UTILITY(U,$J,358.3,22415,1,3,0)
+34 ;;=3^COPD w/ Lower Respiratory Infection
+35 ;;^UTILITY(U,$J,358.3,22415,1,4,0)
+36 ;;=4^J44.0
+37 ;;^UTILITY(U,$J,358.3,22415,2)
+38 ;;=^5008239
+39 ;;^UTILITY(U,$J,358.3,22416,0)
+40 ;;=J44.1^^73^961^16
+41 ;;^UTILITY(U,$J,358.3,22416,1,0)
+42 ;;=^358.31IA^4^2
+43 ;;^UTILITY(U,$J,358.3,22416,1,3,0)
+44 ;;=3^COPD w/ Acute Exacerbation
+45 ;;^UTILITY(U,$J,358.3,22416,1,4,0)
+46 ;;=4^J44.1
+47 ;;^UTILITY(U,$J,358.3,22416,2)
+48 ;;=^5008240
+49 ;;^UTILITY(U,$J,358.3,22417,0)
+50 ;;=I50.22^^73^961^15
+51 ;;^UTILITY(U,$J,358.3,22417,1,0)
+52 ;;=^358.31IA^4^2
+53 ;;^UTILITY(U,$J,358.3,22417,1,3,0)
+54 ;;=3^CHF-Systolic (HFrEF),Chronic
+55 ;;^UTILITY(U,$J,358.3,22417,1,4,0)
+56 ;;=4^I50.22
+57 ;;^UTILITY(U,$J,358.3,22417,2)
+58 ;;=^5007241
+59 ;;^UTILITY(U,$J,358.3,22418,0)
+60 ;;=I50.32^^73^961^13
+61 ;;^UTILITY(U,$J,358.3,22418,1,0)
+62 ;;=^358.31IA^4^2
+63 ;;^UTILITY(U,$J,358.3,22418,1,3,0)
+64 ;;=3^CHF-Diastolic (HFpEF),Chronic
+65 ;;^UTILITY(U,$J,358.3,22418,1,4,0)
+66 ;;=4^I50.32
+67 ;;^UTILITY(U,$J,358.3,22418,2)
+68 ;;=^5007245
+69 ;;^UTILITY(U,$J,358.3,22419,0)
+70 ;;=I50.42^^73^961^12
+71 ;;^UTILITY(U,$J,358.3,22419,1,0)
+72 ;;=^358.31IA^4^2
+73 ;;^UTILITY(U,$J,358.3,22419,1,3,0)
+74 ;;=3^CHF-Combined Systolic & Diastolic,Chronic
+75 ;;^UTILITY(U,$J,358.3,22419,1,4,0)
+76 ;;=4^I50.42
+77 ;;^UTILITY(U,$J,358.3,22419,2)
+78 ;;=^5007249
+79 ;;^UTILITY(U,$J,358.3,22420,0)
+80 ;;=I50.84^^73^961^14
+81 ;;^UTILITY(U,$J,358.3,22420,1,0)
+82 ;;=^358.31IA^4^2
+83 ;;^UTILITY(U,$J,358.3,22420,1,3,0)
+84 ;;=3^CHF-End Stage
+85 ;;^UTILITY(U,$J,358.3,22420,1,4,0)
+86 ;;=4^I50.84
+87 ;;^UTILITY(U,$J,358.3,22420,2)
+88 ;;=^5151391
+89 ;;^UTILITY(U,$J,358.3,22421,0)
+90 ;;=E11.22^^73^961^27
+91 ;;^UTILITY(U,$J,358.3,22421,1,0)
+92 ;;=^358.31IA^4^2
+93 ;;^UTILITY(U,$J,358.3,22421,1,3,0)
+94 ;;=3^DM Type 2 w/ Chronic Kidney Disease
+95 ;;^UTILITY(U,$J,358.3,22421,1,4,0)
+96 ;;=4^E11.22
+97 ;;^UTILITY(U,$J,358.3,22421,2)
+98 ;;=^5002630
+99 ;;^UTILITY(U,$J,358.3,22422,0)
+100 ;;=E11.21^^73^961^28
+101 ;;^UTILITY(U,$J,358.3,22422,1,0)
+102 ;;=^358.31IA^4^2
+103 ;;^UTILITY(U,$J,358.3,22422,1,3,0)
+104 ;;=3^DM Type 2 w/ Nephropathy,Unspec
+105 ;;^UTILITY(U,$J,358.3,22422,1,4,0)
+106 ;;=4^E11.21
+107 ;;^UTILITY(U,$J,358.3,22422,2)
+108 ;;=^5002629
+109 ;;^UTILITY(U,$J,358.3,22423,0)
+110 ;;=E11.42^^73^961^32
+111 ;;^UTILITY(U,$J,358.3,22423,1,0)
+112 ;;=^358.31IA^4^2
+113 ;;^UTILITY(U,$J,358.3,22423,1,3,0)
+114 ;;=3^DM Type 2 w/ Peripheral Neuropathy
+115 ;;^UTILITY(U,$J,358.3,22423,1,4,0)
+116 ;;=4^E11.42
+117 ;;^UTILITY(U,$J,358.3,22423,2)
+118 ;;=^5002646
+119 ;;^UTILITY(U,$J,358.3,22424,0)
+120 ;;=E11.43^^73^961^26
+121 ;;^UTILITY(U,$J,358.3,22424,1,0)
+122 ;;=^358.31IA^4^2
+123 ;;^UTILITY(U,$J,358.3,22424,1,3,0)
+124 ;;=3^DM Type 2 w/ Autonomic Neuropathy
